Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the …
E Van Cutsem, VM Moiseyenko, S Tjulandin, A Majlis… - 2006 - repositorio.uchile.cl
Purpose In the randomized, multinational phase II/III trial (V325) of untreated advanced
gastric cancer patients, the phase II part selected docetaxel, cisplatin, and fluorouracil (DCF) …
gastric cancer patients, the phase II part selected docetaxel, cisplatin, and fluorouracil (DCF) …
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer …
Background Pembrolizumab monotherapy showed durable antitumour activity and
manageable safety in patients with metastatic triple-negative breast cancer. We aimed to …
manageable safety in patients with metastatic triple-negative breast cancer. We aimed to …
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label …
Background Patients with advanced gastric or gastro-oesophageal junction cancer that
progresses on chemotherapy have poor outcomes. We compared pembrolizumab with …
progresses on chemotherapy have poor outcomes. We compared pembrolizumab with …
[PDF][PDF] Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer …
E Van Cutsem, J Tabernero, R Lakomy, H Prenen… - J Clin …, 2012 - researchgate.net
Purpose Treatment for metastatic colorectal cancer (mCRC) commonly involves a
fluoropyrimidine-based chemotherapy regimen such as infusional fluorouracil, leucovorin …
fluoropyrimidine-based chemotherapy regimen such as infusional fluorouracil, leucovorin …
[PDF][PDF] Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results
J O'Shaughnessy, D Miles, S Vukelja… - Journal of clinical …, 2002 - researchgate.net
Purpose: Docetaxel and capecitabine, a tumor-acti-vated oral fluoropyrimidine, show high
single-agent efficacy in metastatic breast cancer (MBC) and synergy in preclinical studies …
single-agent efficacy in metastatic breast cancer (MBC) and synergy in preclinical studies …
[HTML][HTML] Tumor acidity: From hallmark of cancer to target of treatment
A Bogdanov, A Bogdanov, V Chubenko… - Frontiers in …, 2022 - frontiersin.org
Tumor acidity is one of the cancer hallmarks and is associated with metabolic
reprogramming and the use of glycolysis, which results in a high intracellular lactic acid …
reprogramming and the use of glycolysis, which results in a high intracellular lactic acid …
Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial
Background Patients with advanced gastric cancer have a poor prognosis and few
efficacious treatment options. We aimed to assess the addition of cetuximab to capecitabine …
efficacious treatment options. We aimed to assess the addition of cetuximab to capecitabine …
[PDF][PDF] Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the …
Multicenter Phase III Comparison of Cisplatin/S-1 With Cisplatin/Infusional Fluorouracil in
Advanced Gastric or Gastroesophageal Page 1 Multicenter Phase III Comparison of …
Advanced Gastric or Gastroesophageal Page 1 Multicenter Phase III Comparison of …
Durvalumab with or without tremelimumab vs standard chemotherapy in first-line treatment of metastatic non–small cell lung cancer: the MYSTIC phase 3 randomized …
NA Rizvi, BC Cho, N Reinmuth, KH Lee, A Luft… - JAMA …, 2020 - jamanetwork.com
Importance Checkpoint inhibitors targeting programmed cell death 1 or its ligand (PD-L1) as
monotherapies or in combination with anti–cytotoxic T-lymphocyte–associated antigen 4 …
monotherapies or in combination with anti–cytotoxic T-lymphocyte–associated antigen 4 …
[PDF][PDF] Clinical Benefit With Docetaxel Plus Fluorouracil and Cisplatin Compared With Cisplatin and Fluorouracil in a Phase III Trial of Advanced Gastric or …
JA Ajani, VM Moiseyenko, S Tjulandin… - Journal of Clinical …, 2007 - researchgate.net
Purpose For patients with advanced gastric or gastroesophageal cancer (AGGEC) providing
clinical benefit with improved palliation is highly desirable. However, a prospective …
clinical benefit with improved palliation is highly desirable. However, a prospective …